Definium says claims study finds high GAD drug discontinuation, switching rates

Definium Therapeutics reported results from a healthcare claims study in CNS Spectrums showing high switching, discontinuation, and care gaps in GAD pharmacotherapy.

• 55% of newly diagnosed patients stopped initial therapy; 28% added or switched.
• Median discontinuation was 84 days, below the 6-12 month guideline duration.
• Established patients showed 16% discontinuation; 55% added or switched.
• Median discontinuation for established patients was 119 days.
• 57% of newly diagnosed patients who discontinued did not restart during follow-up; median treatment gap for restarters was 146 days.
• The findings were cited as evidence of unmet need for new GAD treatments with faster onset, sustained control, and improved tolerability.